Comparison · NCT02861534-sae
Vericiguat vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Vericiguat vs Placebo: serious adverse events. Trial comparisons, record NCT02861534-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02861534-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.338 | 0.32 | 0.357 | wilson | |
| Risk in group 2 | 0.357 | 0.338 | 0.376 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0184 | -0.0447 | 0.00787 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.948 | 0.879 | 1.02 | log | |
| Odds ratio, group 1 over group 2 | 0.922 | 0.821 | 1.04 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Vericiguat than on Placebo | 54.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Vericiguat | Participants received a starting dose of 2.5 mg of vericiguat taken orally once daily with food, on a background of HF standard of care. The vericiguat dose was uptitrated to 5 mg and to 10 mg. | 852 | 2,519 | EG000 |
| Group 2 | Placebo | Participants received a starting matching placebo dose of 2.5 mg taken orally once daily with food, on a background of HF standard of care. The matching placebo dose was uptitrated to 5 mg and to 10 mg. | 897 | 2,515 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Up to approximately 35 months (through Last Subject Last Visit date of 02-Sept-2019)
Source ClinicalTrials.gov
Trial
- Title
- A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)
- NCT number
- NCT02861534
- Phases
- PHASE3
- Conditions
- Heart Failure, Chronic Heart Failure With Reduced Ejection Fraction
- Interventions
- Vericiguat, Placebo for vericiguat
- Lead sponsor
- Merck Sharp & Dohme LLC
- Results first posted
- 2020-06-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02861534?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02861534-sae